Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: A report from EBMT
Bone Marrow Transplantation, Volume 48, No. 6, Year 2013
Notification
URL copied to clipboard!
Description
In this multicenter retrospective study, the long-term outcomes of 878 adults with AML and refractory anemia with excess blasts (RAEB) with BM blasts <10% who underwent transplantation with an HLA-identical sibling donor between 1998 and 2004 were analyzed according to four regimens of conditioning intensity: reduced-intensity conditioning (RIC) (either intermediate RIC (IntermRIC) or non-myeloablative (NMA) RIC), and myeloablative conditioning (MC) in 718 patients (either conventional MC or hyperintense MC. In multivariate cox analysis, patients undergoing NMA transplantation had lower non-relapse mortality risk in the first 100 days after transplantation (P<0.01), but a higher risk beyond day +100 (P=0.02), as well as higher relapse incidence in the first 12 months (P<0.01), but the risk was similar in all groups beyond 12 months. The probabilities of PFS and OS up to 7 years were significantly lower only in the NMA subgroup (P≤0.01 for both). The 7-year OS was 53%, 29%, 56% and 51%, respectively. Our data suggest that prospective studies comparing RIC regimens (especially IntermRIC) with MC are appropriate in patients with AML and RAEB who are in a non-advanced disease status. © 2013 Macmillan Publishers Limited All rights reserved.
Authors & Co-Authors
Martino, Rodrigo
Spain, Cerdanyola Del Valles
Universitat Autònoma de Barcelona
de Wreede, Liesbeth C.
Netherlands, Leiden
Leids Universitair Medisch Centrum
Fiocco, Marta
Netherlands, Leiden
Leids Universitair Medisch Centrum
van Biezen, Anja A.
Netherlands, Leiden
Leids Universitair Medisch Centrum
Von Dem Borne, P. A.
Netherlands, Leiden
Leids Universitair Medisch Centrum
Hamladji, Rose Marie
Algeria, Algiers
Centre Pierre et Marie Curie
Volin, Liisa
Finland, Helsinki
Helsinki University Hospital
Bornhäuser, Martin
Germany, Dresden
Universitätsklinikum Carl Gustav Carus Dresden
Robin, Marie
France, Paris
Hôpital Saint-louis
Rocha, Vanderson G.
France, Paris
Hôpital Saint-louis
de Witte, Theo J.M.
Netherlands, Nijmegen
Radboud University Medical Center
Kröger, Nikolaus Martin
Germany, Hamburg
Universitätsklinikum Hamburg-eppendorf
Mohty, Mohamad
France, Nantes
Chu de Nantes
Statistics
Citations: 84
Authors: 13
Affiliations: 9
Identifiers
Doi:
10.1038/bmt.2012.236
ISSN:
02683369
e-ISSN:
14765365
Study Design
Cohort Study